Gsk3368715 closed clinical trial
WebDec 17, 2024 · GSK3368715 is a small molecule inhibitor of type I PRMTs currently in clinical development. Here, we evaluate the effect of type I PRMT inhibition on arginine methylation in normal human peripheral blood mononuclear cells and utilize a broad proteomic approach to identify type I PRMT substrates. WebJul 8, 2024 · The current report describes GSK3368715 (EPZ019997), a potent, reversible type I PRMT inhibitor with anti-tumor effects in human cancer models. Inhibition of …
Gsk3368715 closed clinical trial
Did you know?
WebJan 25, 2024 · Fedoriw A, et al. Anti-tumor Activity of the Type I PRMT Inhibitor, GSK3368715, Synergizes with PRMT5 Inhibition through MTAP Loss. Cancer Cell. 2024 Jul 8;36 (1):100-114.e25. doi: 10.1016/j.ccell.2024.05.014. Epub 2024 Jun 27. PMID: 31257072. 制版人：Kira 特别声明：以上内容 (如有图片或视频亦包括在内)为自媒体平台“ … WebPart 2:GSK3368715 dose expansion-solid tumor participants Experimental Eligible participants with relapsed/refractory solid tumors ( pancreas cancer , NSCLC , and …
WebJun 1, 2024 · Notably, GSK3368715, a type I PRMT inhibitor, has entered human clinical trials (NCT03666988), potentially opening up new avenues for the treatment of solid and … WebJul 29, 2024 · GSK3368715 induces time- and dose-dependent accumulation of DLBCL cells in sub-G 1. In contrast, the cytostatic OCI-Ly1 line accumulation of sub-G 1 only detects at the highest concentration of GSK3368715. In vivo, GSK3368715 can completely inhibit tumor growth or cause regressions of tumor models.
WebSo far, three PRMT inhibitors have entered clinical trials, including PRMT5 inhibitor GSK3326595 and JNJ-64619178 as well as PRMT1 inhibitor GSK3368715. PRMT inhibitors with novel mechanism of action and good drug-like properties may shed new light on drug research and development progress. WebMar 10, 2024 · Notably, the type I PRMT inhibitor GSK3368715 is in phase I clinical trials for the treatment of diffuse large B-cell lymphoma and solid tumors (clinicaltrials.gov identifier number: NCT03666988). Additionally, PRMT5 inhibitors JNJ-64619178 and GSK3326595 are currently in phase I clinical trials (ClinicalTrials.gov identifier numbers ...
WebApr 8, 2024 · The metabolic enzyme methionine adenosyltransferase 2A (MAT2A) was recently implicated as a synthetic lethal target in cancers with deletion of the methylthioadenosine phosphorylase (MTAP) gene, wh... Discovery of AG-270, a First-in-Class Oral MAT2A Inhibitor for the Treatment of Tumors with Homozygous MTAP …
WebDrug Profile GSK 3368715 Alternative Names: GSK3368715 Latest Information Update: 22 Aug 2024 Price : $50 * Buy Profile Adis is an information provider. We do not sell or … cabin rentals in southern wisconsinWebApr 1, 2024 · A type I PRMT inhibitor, GSK3368715, has been developed and has entered clinical trials for solid and hematologic malignancies. Although type I PRMTs have been … cabin rentals in southern oklahomaWebGSK3368715 (EPZ019997) significantly effects on the growth of BxPC3 xenografts at all doses tested, reducing tumor growth by 78% and 97% in the 150- and 300-mg/kg dose groups, respectively. MCE has not … club fightingWebMay 18, 2024 · Since the dysregulation of protein arginine methylation is closely associated with cancer development, protein arginine methyltransferases (PRMTs) have garnered significant interest as novel... club fighterWebClinical Trials Detail Study #2024-0666 A phase I, open-label, dose-escalation study to investigate the safety, pharmacokinetics, pharmacodynamics and clinical activity of … club fight backWebMar 15, 2024 · IDEAYA is leading research and development of IDE397 through early clinical development, in collaboration with GlaxoSmithKline (GSK), and is targeting delivery of an option data package to GSK mid-year 2024, following dose selection for an expansion cohort or establishing the MTD. cabin rentals in southwestern paclubfilmothek bjf